

Characterization and in vivo assessment of two newly isolated bacteriophages against a ST13 urinary tract infection Klebsiella pneumoniae strain

Fanny Laforêt^{1,2,*}, Céline Antoine^{1,2}, Bob Blasdel³, Jean-Paul Pirnay⁴, Sylvain Brisse⁵, Abdoulaye Fall⁶, Jean-Noël Duprez¹, Véronique Delcenserie^{2,#} and Damien Thiry^{1,#}

- ¹ Bacteriology Laboratory, Department of Infectious and Parasitic Diseases, FARAH and Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium; fanny.laforet@uliege.be (F.L.); celine.antoine@uliege.be (C.A.); jeannoel.duprez@uliege.be (J.-N.D.)
- ² Food Science Department, FARAH and Faculty of Veterinary Medicine, ULiège, 4000 Liège, Belgium; veronique.delcenserie@uliege.be
- ³ Vésale Bioscience, Vésale Pharmaceutica, 5310 Noville-sur-Mehaigne, Belgium ; <u>bob.blasdel@vesalepharma.com</u>
- ⁴Laboratory for Molecular and Cellular Technology (LabMCT), Queen Astrid Military Hospital, Neder-over-Heembeek, Belgium; jean-paul.pirnay@mil.be
- ⁵ Institut Pasteur, Université de Paris, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France; sylvain.brisse@pasteur.fr
- ⁶Genalyse Partner SA, En Hayeneux 62, 4040 Herstal, Belgium; <u>afa@genalyse.eu</u>
- [#] These authors equally supervised the work
- * Correspondence: fanny.laforet@uliege.be; Tel.: +32-4-366938822
- This research is funded by the Walloon Public Service, BIOWIN, project: Inteliphages.

Introduction

Klebsiella pneumoniae is on the "critical priority" list for the discovery of new control methods due to its antimicrobial resistance. Responsible of some urinary tract infections (UTIs), the bacteriophage therapy represents a promising alternative against the bacteria. The aim of this study was to isolate and characterize new bacteriophages against a K. pneumoniae isolated from UTI and to assess their efficacy in vitro and in vivo in a Galleria (G.) mellonella larvae model.

<u>Material, method and results</u>







SHV-1 • Structural proteins : FimA, B, D, F, G and H

9. Galleria (G.) mellonella survival rates Phages efficacy was tested in this in vivo model using the **MOI 10** and **100** (and **1000** if 100 was not enough). The larvae were **2 times inoculated** (1h between both injections) with different treatment combinaisons (see table below). The survival rates were evaluated each 24h for 72h (via Kaplan-Meier curves and Logrank tests):



For each phage, 120 larvae were divided into 6 groups and inoculated following the same protocol as for the survival experiment (using a **MOI of 100**). The larvae were crushed at 24h and 72h and the **phage** and **bacteria** were titrated in the larvae juice.



- After 24 or 72h : [bacteria] in positive group > treatedinfected groups, [phage] in safety group < treatedinfected groups
- In all the infected groups (treated or not) the [bacteria] or [phage] decreased over time
- Lower [bacteria] with vB_KpnA_K3-ULINTkp2
- Higher [phage] with vB_KpnA_K3-ULINTkp1

Conclusion

6

0.8

0,6

In conclusion, these two newly isolated Klebsiella phages demonstrated their efficacy in vitro and in vivo by increasing the survival of G. mellonella larvae infected with a K. pneumoniae ST13 K3, even if this did not result in a complete elimination of the inoculated bacteria. Although these phages are genomically closely related, vB_KpnA_K3-ULINTkp2 showed a better efficacy in the in vivo G. mellonella model and a broader host spectrum than vB_KpnA_K3-ULINTkp1.

LIÈGE BIOWN

- K. pneumoniae SB5890: ST17



Wallonie



VFSALF

